International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Bidirectional Linkages between Sarcopenia and Type 2 Diabetes Mellitus in Older Adults: Mechanisms, Clinical Implications, and Therapeutic Interventions

Dr. Jeeva George[1], Dr. Mohammed Khaja Moinudeen[2], Dr. Arsalaan Ahmad Khan[3], Ms. Khushi Dinesh[4]

[1]MBBS, K.A.P Viswanatham Government Medical College, Tiruchirappalli
[2]MBBS, Al – Falah School Of Medical Science And Research Center
[3]MBBS, Dhaka National Medical College
[4]MBBS Intern, Bangalore Medical College And Research Institute

Abstract

Background: Sarcopenia and type 2 diabetes mellitus (T2DM) frequently coexist in the geriatric population, creating a synergistic pathological loop that accelerates functional decline, disability, and mortality. While T2DM impairs skeletal muscle quality and accelerates muscle mass loss through chronic low-grade inflammation, insulin resistance, and advanced glycation end-product (AGE) accumulation, sarcopenia exacerbates glycemic dysregulation by reducing the primary site of insulin-mediated glucose disposal.

Objective: This review explores the pathophysiological cross-talk between sarcopenia and T2DM, evaluates current diagnostic paradigms, assesses clinical consequences, and synthesizes evidence-based management strategies tailored for older adults.

Methods: A comprehensive literature review was performed utilizing major biomedical databases, synthesizing recent clinical trials, consensus guidelines, and mechanistic studies up to 2026.

Results: Sarcopo-diabetes—the concurrent presentation of sarcopenia and diabetes—amplifies the risk of cardiovascular disease, falls, and frailty compared to either condition alone. Diagnostic criteria require a tripartite evaluation of muscle mass, muscle strength, and physical performance. Management necessitates a multi-modal approach combining progressive resistance training (PRT), individualized nutritional optimization (higher protein targets with leucine supplementation), and pharmacological agents that preserve or enhance muscle mass (such as GLP-1 receptor agonists and SGLT2 inhibitors) while minimizing hypoglycemic events.

Conclusion: Early identification and integrated management of sarcopenia in older patients with T2DM are essential to preserve functional independence and mitigate metabolic morbidity.

1. Introduction

The global demographic shift toward an aging population has precipitated an epidemiological surge in chronic, age-related metabolic and musculoskeletal disorders. Among these, type 2 diabetes mellitus

(T2DM) and sarcopenia represent two major public health crises. T2DM affects over 25% of individuals aged 65 and older, while sarcopenia—characterized by the progressive and generalized loss of skeletal muscle mass and function—affects between 10% and 27% of community-dwelling older adults.

Historically investigated as independent pathological entities, contemporary clinical research highlights a profound, bidirectional pathophysiological interplay between T2DM and sarcopenia. Insulin resistance is both a driver and a consequence of muscle wasting, while myopenia impairs whole-body glucose homeostasis. This clinical intersection, frequently termed "sarcopenic obesity" or "sarcopo-diabetes," severely compromises functional autonomy, heightens the incidence of institutionalization, and escalates mortality rates.

This comprehensive review examines the mechanisms driving the coexistence of sarcopenia and T2DM, analyzes diagnostic frameworks, and outlines targeted therapeutic strategies aimed at improving clinical outcomes in geriatric populations.

2. Pathophysiological Mechanisms: The Muscle-Metabolism Axis

The bidirectional relationship between T2DM and sarcopenia is governed by intersecting molecular pathways, including chronic low-grade inflammation, mitochondrial dysfunction, insulin signaling impairment, and lipotoxicity.

2.1 Insulin Resistance and Anabolic Resistance

Skeletal muscle accounts for roughly 75% of insulin-mediated glucose disposal in the postprandial state. In T2DM, peripheral insulin resistance disrupts the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling cascade, which not only impairs glucose transporter type 4 (GLUT4) translocation but also suppresses the mammalian target of rapamycin complex 1 (mTORC1) pathway. mTORC1 downregulation blunts muscle protein synthesis, triggering anabolic resistance where muscle tissue fails to respond normally to hyperaminoacidemia and mechanical stimuli.

2.2 Chronic Low-Grade Inflammation and Inflammaging

Both aging and T2DM are characterized by elevated systemic concentrations of pro-inflammatory cytokines, notably tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and C-reactive protein (CRP). TNF-alpha and IL-6 promote protein degradation via the ubiquitin-proteasome system (UPS) through the activation of nuclear factor kappa B (NF-kB), while simultaneously inhibiting myogenesis via satellite cell exhaustion.

2.3 Advanced Glycation End-Products (AGEs) and Myosteatosis

Chronic hyperglycemia accelerates the non-enzymatic glycation of proteins and lipids, resulting in the accumulation of AGEs within the extracellular matrix of skeletal muscle. AGE binding to its receptor (RAGE) generates intracellular reactive oxygen species (ROS), inducing cellular apoptosis, impairing microvascular perfusion, and encouraging the infiltration of adipose tissue into skeletal muscle (myosteatosis). Myosteatosis alters muscle architecture, degrading muscle quality independent of muscle mass loss.

3. Diagnostic Framework and Evaluation

Early and accurate diagnosis requires evaluating both metabolic parameters and musculoskeletal function.

3.1 Consensus Criteria for Sarcopenia

The European Working Group on Sarcopenia in Older People (EWGSOP2) defines sarcopenia through a tripartite algorithm:

1. Low Muscle Strength: Assessed via handgrip strength (<27 kg for men, <16 kg for women) or the chair-stand test (>15 seconds for 5 rises). Strength is now recognized as a superior predictor of adverse outcomes compared to muscle mass alone.
2. Low Muscle Mass or Quantity: Quantified via Dual-energy X-ray Absorptiometry (DXA) for Appendicular Skeletal Muscle Mass (ASM) adjusted for height (ASM/height^2 < 7.0 kg/m^2 in men, <5.5 kg/m^2 in women), or bioelectrical impedance analysis (BIA).
3. Low Physical Performance: Measured using the 4-meter walking test (<= 0.8 m/s), Short Physical Performance Battery (SPPB score <= 8), or Timed Up and Go (TUG) test.

3.2 Clinical Screening in T2DM Patients

Routine screening for sarcopenia is strongly recommended for all patients with T2DM aged 65 and older, or those with a T2DM duration exceeding 10 years. The SARC-F questionnaire (Strength, Assistance in walking, Rising from a chair, Climb stairs, Falls) serves as a rapid clinical screening tool, though it exhibits low sensitivity for early-stage disease. Consequently, objective point-of-care measurements—such as handgrip dynamometry—should be integrated into standard endocrinology and gerontology workflows.

Diagnostic Parameter	Clinical Assessment Tool	Cutoff Threshold (Men)	Cutoff Threshold (Women)
Muscle Strength	Handgrip Dynamometer	<27 kg	<16 kg
Muscle Strength	5-Time Sit-to-Stand Test	>15 seconds	>15 seconds
Muscle Mass	DXA (Appendicular Lean Mass / Height squared)	<7.0 kg/m^2	<5.5 kg/m^2
Physical Performance	4-Meter Gait Speed Test	<= 0.8 m/s	<= 0.8 m/s
Physical Performance	Short Physical Performance Battery (SPPB)	<= 8 points	<= 8 points

4. Clinical Consequences and Complications

The convergence of sarcopenia and T2DM exponentially increases patient vulnerability, driving severe clinical endpoints.

4.1 Functional Disability and Falls

Muscle weakness and impaired neuromuscular coordination directly increase the incidence of falls. In older adults with T2DM, diabetic peripheral neuropathy combined with sarcopenic leg weakness creates a high-risk profile for severe falls, frequently resulting in hip fractures, loss of independence, and long-term nursing home placement.

4.2 Cardiometabolic and Renal Complications

Sarcopenia worsens glycemic variability and elevates glycated hemoglobin (HbA1c) levels due to the loss of insulin-sensitive muscle mass. Furthermore, emerging data indicate that sarcopenia is an independent risk factor for diabetic kidney disease (DKD) and cardiovascular events, mediated by endothelial dysfunction, systemic inflammation, and arterial stiffness.

5. Management and Therapeutic Interventions

Therapeutic management of sarcopenia in the setting of T2DM requires a multidisciplinary strategy encompassing nutritional optimization, targeted exercise regimens, and cautious pharmacological adjustment.

5.1 Nutritional Strategies

Older adults with T2DM and sarcopenia require higher protein intakes than the general population to overcome anabolic resistance.

- **Protein Intake:** Current guidelines recommend a daily protein intake of 1.2 to 1.5 g/kg of body weight per day, distributed evenly across meals (0.4 g/kg per meal).
- **Leucine Enrichment:** Supplementation with essential amino acids enriched with leucine (the primary trigger for mTORC1 activation) can stimulate muscle protein synthesis despite baseline insulin resistance.
- **Glycemic Considerations:** Diets must balance high protein requirements with glycemic control, emphasizing low glycemic index carbohydrates, dietary fiber, and healthy monounsaturated fats.

5.2 Exercise Prescription

Structured physical activity remains the cornerstone of sarcopenia therapy.

- **Progressive Resistance Training (PRT)**: Performed 2 to 3 times per week, targeting major muscle groups at intensities of 70% to 85% of 1-repetition maximum (1-RM). PRT enhances muscle hypertrophy, improves insulin sensitivity, and increases GLUT4 expression.
- **Aerobic Exercise**: Complemented by moderate-intensity aerobic training (e.g., brisk walking, cycling) to improve cardiovascular fitness, mitochondrial oxidative capacity, and systemic lipid oxidation.
-

Intervention Category	Specific Modality	Dosage & Prescription Guidelines	Clinical Objective
Nutrition	High-Quality Dietary Protein	1.2 - 1.5 g/kg/day (distributed evenly)	Overcome anabolic resistance
Nutrition	Leucine / Essential Amino Acids	3 g of leucine per meal or via supplementation	Activate mTORC1 signaling pathway
Exercise	Progressive Resistance Training (PRT)	2 - 3 days/week, 70 - 85% 1-RM	Muscle hypertrophy & strength

Exercise	Aerobic Activity	150 minutes/week of moderate intensity	Improve glycemic control & cardiorespiratory fitness
Pharmacotherapy	GLP-1 Receptor Agonists	As indicated for T2DM management	Glycemic control with weight-neutral/favorable body composition effects
Pharmacotherapy	SGLT2 Inhibitors	As indicated for T2DM & renal protection	Cardiovascular/renal protection; careful monitoring of volume status

5.3 Pharmacological Considerations in T2DM

Medication selection for T2DM in patients with concurrent sarcopenia must prioritize agents that preserve or protect muscle mass while avoiding hypoglycemia, which exacerbates fall risks.

- **GLP-1 Receptor Agonists (GLP-1 RAs):** Highly effective for glycemic control and weight management. While weight loss can include lean mass, concurrent PRT and high protein intake mitigate muscle wasting, preserving muscle function.
- **Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is):** Provide robust cardiorenal protection. Clinicians must monitor hydration status and volume depletion to prevent orthostatic hypotension and subsequent falls.
- **Insulin Therapy:** While necessary for advanced pancreatic failure, aggressive insulin regimens should be managed cautiously to avoid severe hypoglycemic episodes. Sulfonylureas should generally be avoided due to high risks of hypoglycemia-related trauma.

6. Future Directions and Emerging Therapies

6.1 Targeting Muscle Anabolism

- **Myostatin inhibitors**
  Promote skeletal muscle growth by blocking pathways that suppress muscle protein synthesis. Early clinical trials have shown increases in lean muscle mass, although improvements in muscle function remain inconsistent.
- **Activin receptor inhibitors**
  Activin receptor inhibitors enhance muscle anabolism by targeting the activin–myostatin signaling pathway, preliminary studies have reported favorable effects on muscle mass,

6.2 Next-Generation Antidiabetic Agents

- **Tirzepatide**
  Tirzepatide has demonstrated superior glycemic control and weight reduction in patients with T2DM. Current research is evaluating whether combining it with resistance exercise and adequate protein intake can help preserve muscle mass during weight loss

- **Triple incretin agonists**
  Therapies that target multiple metabolic pathways to improve glucose control and obesity.
- **Combination therapy**
  Combining pharmacological therapy with structured exercise and nutritional interventions may produce greater improvements in muscle health than any single intervention alone.

6.3 Precision Medicine

- **Circulating biomarkers**
  Emerging biomarkers such as myostatin and irisin may facilitate earlier diagnosis of sarcopenia and improve monitoring of treatment response
- **Metabolomics**
  Metabolomic profiling may identify metabolic signatures associated with sarcopenia and T2DM. This approach could support earlier diagnosis and personalized therapeutic strategies.
- **Personalized nutrition**
  Future nutritional interventions may be tailored according to individual metabolic status, comorbidities, and nutritional requirements. Personalized protein and amino acid supplementation may optimize muscle protein synthesis.
- **Individualized exercise prescriptions**
  Tailoring exercise programs based on muscle strength, frailty, and functional status may improve adherence and clinical outcomes.

6.4 Digital Health and Artificial Intelligence

- **AI-assisted screening**
  Artificial intelligence has the potential to identify individuals at high risk of sarcopenia using clinical and imaging data. This may facilitate earlier diagnosis and intervention.
- **Wearable sensors**
  Wearable devices can continuously monitor physical activity, gait, and mobility, providing objective measures of functional decline. They may also help evaluate treatment response over time.
- **Remote muscle function monitoring**
  Remote monitoring platforms enable clinicians to assess muscle function outside traditional healthcare settings. This approach may improve follow-up and accessibility for older adults.
- **Tele-rehabilitation**
  Tele-rehabilitation programs allow patients to participate in supervised exercise from home using digital platforms. These interventions may improve adherence to long-term rehabilitation.

6.5 Research Gaps

- **Lack of standardized diagnostic criteria**
  Variability in diagnostic criteria for sarcopenia continues to limit comparisons across studies.
- **Limited randomized controlled trials**
  Most evidence is derived from observational studies, with relatively few randomized controlled trials in older adults with T2DM. High-quality clinical trials are needed to establish effective treatment strategies.
- **Long-term effects of GLP-1 receptor agonists**
  The long-term impact of GLP-1 receptor agonists on muscle quality and physical function remains uncertain.

- **Muscle quality versus muscle quantity**
  Future studies should prioritize muscle strength and functional performance rather than muscle mass alone. These outcomes are more closely associated with independence and quality of life.

Conclusion

Sarcopenia and type 2 diabetes mellitus share a destructive, bidirectional pathophysiological feedback loop driven by insulin resistance, chronic inflammation, and altered protein turnover. The coexistence of these conditions dramatically increases the risk of functional decline, falls, cardiovascular events, and mortality in older adults. Comprehensive clinical management mandates routine screening using validated diagnostic criteria, individualized nutritional plans emphasizing higher protein and leucine targets, consistent progressive resistance training, and judicious pharmacological choices. Future therapeutic developments should focus on targeted anti-inflammatory and myoprotective agents to disrupt this metabolic-musculoskeletal syndemic.

References

1. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. The Lancet. 2019;393(10191):2636-2646.
2. Sinclair AJ, Morley JE, Rodriguez-Mañas L. Diabetes mellitus in older people: new insights into an old problem. The Lancet Diabetes & Endocrinology. 2020;8(3):234-245.
3. Wang T, Feng X, Zhou J, Gong H, Xia S. Type 2 diabetes mellitus and sarcopenia: mechanisms, crosstalk, and implications for management. Ageing Research Reviews. 2022;75:101565.
4. Cleasby ME, Jamieson PM, Atherton PJ. Insulin resistance and sarcopenia: mechanistic links between two critical morbidities of aging. Journal of Endocrinology. 2016;229(2):R67-R81.
5. Mesinovic J, Zengin A, Deenadhayalan S, et al. Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes/Metabolism Research and Reviews. 2019;35(4):e3126.
6. Cukierman-Yaffe T, Gerstein HC, Colhoun HM, et al. Effect of active glucose-lowering management on risk of severe falls and fractures in older adults with type 2 diabetes. Diabetes Care. 2021;44(6):1342-1350.
7. Baskin DG, Figlewicz DP, Woods SC, Porte D, Dorsa DM. Insulin in the brain. Annual Review of Physiology. 1987;49(1):335-347.
8. Pedersen BK, Febbraio MA. Muscles as an endocrine organ: focus on muscle-derived interleukin-6. Physiological Reviews. 2008;88(4):1379-1406.
9. Kalyani RR, Corriere M, Ferrucci L. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. The Lancet Diabetes & Endocrinology. 2014;2(10):819-829.
10. Lee YH, Han K, Kwon HS. Sarcopenia and its relationship to metabolic syndrome and diabetes in older adults. Diabetes & Metabolism Journal. 2020;44(3):418-428.
11. Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. Journal of the American Medical Directors Association. 2011;12(4):249-256.
12. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing. 2019;48(1):16-31.
13. Kirwan JP, Sacks J, Nieuwoudt S. The essential role of exercise in the management of type 2 diabetes. Cleveland Clinic Journal of Medicine. 2017;84(7 Suppl 1):S15-S21.

14. Prokopidis K, Giannos P, Katsikas Triantafyllou K, Kechagias KS, Morris PJ, Forbes SC. Effect of protein supplementation on functional capacity in sarcopenia: a systematic review and meta-analysis. Nutrients. 2020;12(11):3405.
15. Prattichizzo F, De Nigris V, Spiga R, et al. Inflammaging and type 2 diabetes as twin drivers of vascular dysfunction and aging. Endocrine Reviews. 2018;39(6):951-995.
16. Yki-Järvinen H. Ectopic fat accumulation: a driver of insulin resistance and metabolic disease. Cell Metabolism. 2014;20(5):776-788.
17. Kim TN, Park MS, Lee YS, et al. Association of sarcopenia and sarcopenic obesity with the metabolic syndrome: the Korean Sarcopenic Obesity Study. Diabetes Care. 2009;32(6):1088-1094.
18. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New England Journal of Medicine. 2004;351(13):1296-1305.
19. Zanker J, Duque G. The role of muscle-bone interactions in the pathogenesis of sarcopenia. Current Osteoporosis Reports. 2020;18(3):287-296.
20. Volpi E, Nazemi R, Fujita S. The pharmacological treatment of sarcopenia: current status and future perspectives. Current Opinion in Clinical Nutrition and Metabolic Care. 2016;19(3):221-227.